Table 1 Patient characteristics for MS patients with RT
From: Clinicopathologic features and responses to radiotherapy of myeloid sarcoma
Patient no. | Age | Gender | Underlying disease | GS site for radiotherapy | Timing of GS emergence | Cytogenetics |
|---|---|---|---|---|---|---|
1 | 62 | F | AML-M2 | Skin | Relapse after chemotherapy, BM also (+) | Normal |
2 | 50 | M | CML | Anus | CML in blast crisis | 47 XXY, inv(11) |
3 | 83 | M | AML-M4 | Skin | Found at initial presentation with BM (+) | t(2;14), NPM(-), FLT3(-) |
4 | 55 | M | AML-M1 | Spinal cord | Relapse after chemotherapy, BM also (+) | t(9;22) Philadelphia chromosome (+) |
5 | 58 | M | AML-M1 | Skin (7 lesions) | Relapse after BMT, BM also (+) | Normal |
6 | 6 | F | CML | Bone (right femur) | CML in blast crisis | t(9;22) Philadelphia chromosome (+) |
7 | 71 | F | MDS- RAEB 2 | Brain | - | Normal |
8 | 41 | F | AML-M2 | Cervix | Relapse after BMT, BM (-) | t(8;21) |
| Â | Â | Â | Â | Right breast | Relapse after BMT, BM (-) | Â |
9 | 42 | M | de novo sarcoma | Right nipple | Found at presentation, BM (-) | Normal |
| Â | Â | Â | Â | Brain | Relapse after chemotherapy, BM also (+) | Â |
| Â | Â | Â | Â | Paranasosinus | Relapse after chemotherapy, BM also (+) | Â |
10 | 56 | M | CML | Spinal cord | CML in blast crisis | Normal |
11 | 22 | M | AML-M4 | Skin (11 lesions) | Relapse after BMT, BM (-) | del(1)(p32p36), t(10;11)(p13;q13) |
12 | 44 | F | CML | Right breast | CML in blast crisis receiving BMT. relapse after BMT, BM (-) | Normal |
13 | 75 | F | AML-M2 | Skin | Found at initial presentation with BM (+) | del(15)(q22q35) |
14 | 29 | F | AML-M2 | Pituitary gland | Relapse after BMT, BM (-) | Normal |
15 | 32 | F | AML-M1 | Right breast | Relapse after BMT, BM (-) | Normal |
| Â | Â | Â | Â | Left breast | Relapse after BMT, BM (-) | Â |
16 | 47 | M | AML-M1 | Brain | Relapse after chemotherapy, BM also (+) | Normal |
| Â | Â | Â | Â | Spinal cord | Relapse after chemotherapy, BM also (+) | Â |
17 | 47 | F | AML-M2 | Skin | Relapse after chemotherapy, BM also (+) | t(8;21) |
18 | 40 | M | AML-M5 | Skin | Emerging during chemotherapy and persistent after BMT, BM (+) | -3p,t(5;17)(q15;q22), t(11;19)(q23;p13),-17,19p; der(19)t(17;19)(q11;p11), t(11;12)(p15;q13), NPM(-), FLT3(-) |
19 | 42 | F | AML-M1 | Right inguinal area | Found at initial presentation with BM (+) | Normal |
20 | 4 | M | AML-M2 | Bone (left tibia) | Relapse after BMT, BM also (+) | t(8;21), AML1-ETO fusion transcription (+) |
| Â | Â | Â | Â | Left buccal mucosa | Relapse after BMT, BM also (+) | Â |
| Â | Â | Â | Â | Bone (right foot) | Relapse after BMT, BM also (+) | Â |